FINWIRES · TerminalLIVE
FINWIRES

最新情報:市場の噂:イーライリリー社、買収資金調達のため約80億ドルの社債発行を計画

By

-- (第4段落に同社の回答を追記。) イーライリリー(LLY)は、買収攻勢の資金を調達するため、投資適格債の発行で約80億ドルを調達する計画だと、ブルームバーグが水曜日に報じた。関係者筋の話として伝えられている。 報道によると、同社は償還期間が2年から40年まで、最大8つのトランシェに分けて債券を発行する予定だ。 ブルームバーグによると、調達資金は一般的な企業目的のほか、センテッサ・ファーマシューティカルズ(CNTA)とケロニア・セラピューティクスの買収に伴う現金対価および関連費用の一部または全部に充当される可能性がある。 イーライリリーの広報担当者は、投資適格債市場への参入を歓迎すると述べた。好調な第1四半期決算、S&Pによる格付けのAA-(見通しはポジティブ)への引き上げ、そして良好な市場環境を背景に、投資家の関心が高まっていることに勇気づけられていると、広報担当者は付け加えた。 (マーケットチャッターのニュースは、世界中の市場専門家との会話から得られた情報に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれている可能性があります。正確性は保証されません。)

Price: $992.35, Change: $+3.48, Percent Change: +0.35%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL